TARS stock forecast
Our latest prediction for Tarsus Pharmaceuticals Inc's stock price was made on the Oct. 23, 2023 when the stock price was at 13.05$.
In the short term (2weeks), TARS's stock price should underperform the market by -0.77%. During that period the price should oscillate between -8.52% and +7.79%.
In the medium term (3months), TARS's stock price should underperform the market by -2.27%. During that period the price should oscillate between -28.69% and +6.80%.Get email alerts
Create a solid portfolio with TARS
About Tarsus Pharmaceuticals Inc
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.
At the moment the company generates 11M USD in revenues.
On its last earning announcement, the company reported a loss of -3.79$ per share.
The book value per share is 8.02$
Three months stock forecastOct. 23, 2023
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|